Chordoma is a type of bone cancer in which the tissues of the bone start growing in an uncontrollable manner. This type of tumor usually occurs at the base of the skull or along the spinal disks. The tumor is typically malignant in nature. In most cases, the bone cancer is a result of other cancers. The primary symptom of the bone cancer is severe and intolerable bone pain that increases over time. Additionally, side effects such as weight reduction, weakness, bone cracks, fever, osteoporosis, and osteopenia and muscle pain can be found. Tests for chordoma may include profound investigation of the patient's medical history and reasons for pain. Later, the finding of the bone malignancy is completed by utilizing imaging investigations such as CT scan, MRI, bone examining, and PET scan. Biopsy test is additionally used for the analysis and confirmation of the disease.
The prevelance of chordoma is observed to be twice in men in than in women. In addition, the majority of tumors are found in patients aged between 50 and 70 years. Tumor immunotherapy has become more efficient and is chosen as a mode of treatment. It essentially enhances the survival of patients in approved indications. Rise in prevalence of bone malignancy, increase in government activities for bone cancer awareness, and increase in the geriatric population are major factors responsible for the expansion of the chordoma disease market.
The global chordoma disease market can be segmented based on diagnosis, treatment, end-user, and region. Based on diagnosis, the global market can be classified into blood tests, imaging, biopsy, and others. The imaging segment can be further categorized into magnetic resonance imaging (MRI), Xray, positron emission tomography (PET) scanning, computed tomography (CT) scan, and bone scan. In terms of treatment, the global chordoma disease market can be split into chemotherapy, cryosurgery, radiosurgery, targeted therapy, radiation therapy, surgical treatments, and others. The surgical treatments segment can be further divided into radical resections, spinal chordoma, sacral chordoma, skull base chordoma, and others. The chemotherapy segment can be further sub-segmented into doxorubicin, methotrexate, and others. Additionally, the targeted therapy segment can be further categorized into bevacizumab, erlotinib, and others. Based on end-user, the global chordoma disease market can be divided into hospitals, clinics, cancer care centers, and others. The hospitals segment is expected to be highly lucrative owing to the preference of treatment in hospitals.
In terms of region, the global chordoma disease market can be segmented into Asia Pacific, North America, Western Europe, Eastern Europe, Latin America, Middle East & Africa. Among these, North America and Europe accounted for a prominent share of the chordoma disease market, followed by Asia Pacific. The U.S. dominated the chordoma disease market in North America, due to factors such as technological advancements, extensive R&D, and increasing healthcare awareness about the treatment and management of chordoma. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. New product launches, favorable regulations, and rise in awareness are likely to drive the market in Asia Pacific during the forecast period.
Key players operating in the global chordoma disease market are AstraZeneca plc, Actavis plc, Celgene Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Pfizer, Inc., Bayer AG, Amgen, Inc., Bristol-Myers Squibb and Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.